Related Experiment Video
Updated: Mar 27, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Neuroendocrine carcinoma of the bladder: A single centre retrospective study]
I Ayedi1, I Abdelli1, H Chaabouni1
1Service de carcinologie médicale, CHU Habib-Bourguiba, route Elain km 1, 3027 Sfax, Tunisie.
Purpose:
Neuroendocrine carcinoma of the bladder is a rare tumour representing 0.5 to 1% of bladder tumours. It is a specific histological entity characterized by rapid metastatic dissemination and poor prognosis. The aim of this study was to describe the epidemiological, clinical, therapeutic modalities and the evolutive aspects of patients receiving a treatment for bladder neuroendocrine carcinoma.
Patients And Methods:
Between January 2004 and January 2014, seven patients received a treatment for a neuroendocrine carcinoma of the bladder, at the department of oncology, Habib-Bourguiba Hospital, in Sfax, Tunisia.
Results:
The median age was 58 years. All patients were male. Neuroendocrine carcinoma was pure in four cases and associated with urothelial carcinoma in the other three cases. Two patients were diagnosed at a metastatic stage. A cystectomy was performed in two cases. One patient received a chemotherapy and radiotherapy. The other four patients received chemotherapy alone. A single case of complete remission was observed. Median survival was 15 months (5-30 months). One patient is still alive 30 months after diagnosis.
Conclusion:
The management of neuroendocrine carcinoma of the bladder is not standardized and requires a multidisciplinary consultation.
